Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
Nakamae H, Terada Y, Nakane T, Koh H, Nakamae M, Aimoto R, Hirose A, Hayashi Y, Nishimoto M, Inoue E, Yoshimura T, Inoue A, Koh KR, Yamane T, Hino M. Nakamae H, et al. Among authors: hayashi y. Gan To Kagaku Ryoho. 2010 Sep;37(9):1691-5. Gan To Kagaku Ryoho. 2010. PMID: 20841930 Japanese.
Immunoglobulin prophylaxis against cytomegalovirus infection in patients at high risk of infection following allogeneic hematopoietic cell transplantation.
Ichihara H, Nakamae H, Hirose A, Nakane T, Koh H, Hayashi Y, Nishimoto M, Nakamae M, Yoshida M, Bingo M, Okamura H, Aimoto M, Manabe M, Hagihara K, Terada Y, Nakao Y, Hino M. Ichihara H, et al. Among authors: hayashi y. Transplant Proc. 2011 Dec;43(10):3927-32. doi: 10.1016/j.transproceed.2011.08.104. Transplant Proc. 2011. PMID: 22172874 Clinical Trial.
Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.
Nakane T, Nakamae H, Koh H, Nakamae M, Hayashi Y, Nishimoto M, Yoshimura T, Inoue E, Inoue A, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Hino M. Nakane T, et al. Among authors: hayashi y. Int J Hematol. 2011 Apr;93(4):509-516. doi: 10.1007/s12185-011-0805-z. Epub 2011 Mar 12. Int J Hematol. 2011. PMID: 21394567
Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.
Koh H, Nakamae H, Hagihara K, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto Y, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Ohsawa M, Hino M. Koh H, et al. Among authors: hayashi y. J Exp Clin Cancer Res. 2011 Apr 10;30(1):36. doi: 10.1186/1756-9966-30-36. J Exp Clin Cancer Res. 2011. PMID: 21477348 Free PMC article.
Eosinophilia, regardless of degree, is related to better outcomes after allogeneic hematopoietic stem cell transplantation.
Nakane T, Nakamae H, Hirose A, Nakamae M, Koh H, Hayashi Y, Nishimoto M, Umemoto Y, Yoshimura T, Bingo M, Okamura H, Yoshida M, Ichihara H, Aimoto M, Terada Y, Nakao Y, Ohsawa M, Hino M. Nakane T, et al. Among authors: hayashi y. Intern Med. 2012;51(8):851-8. doi: 10.2169/internalmedicine.51.6726. Epub 2012 Apr 15. Intern Med. 2012. PMID: 22504238 Free article.
HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome.
Nakamae H, Koh H, Katayama T, Nishimoto M, Hayashi Y, Nakashima Y, Nakane T, Nakamae M, Hirose A, Hino M. Nakamae H, et al. Among authors: hayashi y. Exp Hematol. 2015 Nov;43(11):921-929.e1. doi: 10.1016/j.exphem.2015.07.006. Epub 2015 Aug 15. Exp Hematol. 2015. PMID: 26284307 Free article.
Diagnostic value of serum ferritin and the risk factors and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation.
Nanno S, Koh H, Nakashima Y, Katayama T, Okamura H, Koh S, Yoshimura T, Nishimoto M, Hayashi Y, Nakamae M, Hirose A, Nakane T, Hino M, Nakamae H. Nanno S, et al. Among authors: hayashi y. Leuk Lymphoma. 2017 Jul;58(7):1664-1672. doi: 10.1080/10428194.2016.1262034. Epub 2016 Dec 6. Leuk Lymphoma. 2017. PMID: 27919187
8,245 results